New study links inherited genetic variant to poorer outcome for myeloma patients

Everyone’s genes are slightly different. The differences are grouped into categories, which are called polymorphisms. A gene can be different at a single point—one of the nucleotides which string together the DNA chain of genes and sequences controlling gene function. A single-point difference is called a single-nucleotide polymorphism (SNP).

New drug data challenge the ways we treat myeloma

At the recent annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA), important data were presented on the monoclonal antibodies elotuzumab and daratumumab. The first acts against SLAMF7 and the second against CD38. These new targets on the surface of myeloma cells provide ways to attack myeloma separate from traditional chemotherapy and the immunomodulatory drugs (IMiDs) or proteasome inhibitor “novel” agents.

The Value of Annual PET/CT as a Screening Tool for Myeloma Patients

In last week’s blog, How to Be Safer as You Live Longer,” I cited the value of annual PET/CT as a screening tool to monitor low-level myeloma, detect hidden infection or an early second cancer. This prompted one reader to comment that “Medicare and supplemental insurance companies will not yet cover the cost of the procedure as a screening tool” and to ask for some “practical help” to obtain coverage.

Diagnosing Myeloma Early: New IMWG Guidelines

For some time, members of theInternational Myeloma Working Group (IMWG), the IMF's research division, have been trying to identify and describe a group of patients without 

The Lighter Side Of Stockholm: The Debate, The International Journalist Workshop, And More

As it approached 11 p.m. on our first night in Stockholm, the IMF team started to experience the lighter side of Stockholm: it was not yet dark! There was a rose-colored glow in the clouds to the west as midsummer's day was approaching in a few days.

Pages